Innovus Pharmaceuticals 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 10, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	INNOVUS PHARMACEUTICALS, INC.
Entity Central Index Key	1,411,879
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	INNV
Entity Common Stock, Shares Outstanding		164,434,088
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 1,315,059	$ 829,933
Accounts receivable, net	27,526	33,575
Prepaid expense and other current assets	265,217	863,664
Inventories	640,055	599,856
Total Current Assets	2,247,857	2,327,028
Property and equipment, net	31,442	29,569
Deposits	14,958	14,958
Goodwill	952,576	952,576
Intangible assets, net	4,430,572	4,903,247
Total assets	7,677,405	8,227,378
CURRENT LIABILITIES
Accounts payable and accrued expenses	1,356,057	1,210,050
Accrued compensation	1,201,187	767,689
Deferred revenue and customer deposits	0	11,000
Accrued interest payable	21,353	47,782
Derivative liabilities - embedded conversion feature	0	319,674
Derivative liabilities - warrants	74,151	164,070
Contingent consideration	54,959	170,015
Short-term loan payable	57,590	0
Current portion of notes payable, net of debt discount of $71,531 and $216,403, respectively	722,466	626,610
Convertible debentures, net of debt discount of $0 and $845,730, respectively	0	714,192
Total current liabilities	3,487,763	4,031,082
Accrued compensation - less current portion	1,531,904	1,531,904
Notes payable, net of current portion and debt discount of $0 and $468, respectively	0	54,517
Contingent consideration - less current portion	1,435,499	1,515,902
Total non-current liabilities	2,967,403	3,102,323
Total liabilities	6,455,166	7,133,405
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Preferred stock: 7,500,000 shares authorized, at $0.001 par value, no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	0	0
Common stock: 292,500,000 shares authorized, at $0.001 par value, 155,438,995 and 121,694,293 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	155,439	121,694
Additional paid-in capital	35,211,043	30,108,028
Accumulated deficit	(34,144,243)	(29,135,749)
Total stockholders' equity	1,222,239	1,093,973
Total liabilities and stockholders’ equity	$ 7,677,405	$ 8,227,378

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Notes payable, discount, current	$ 104,788	$ 216,403
Debt discount, debenture, current	0	845,730
Notes payable, discount, non current	$ 0	$ 468
Preferred stock, shares authorized	7,500,000	7,500,000
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	292,500,000	292,500,000
Common stock, par value	$ 0.001	$ .001
Common stock, shares issued	15,543,899	121,694,293
Common stock, shares outstanding	15,543,899	121,694,293

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net revenue:
Product sales, net	$ 2,218,343	$ 1,882,129	$ 6,426,790	$ 3,126,112
License revenues	2,500	0	10,000	1,000
Net revenue	2,220,843	1,882,129	6,436,790	3,127,112
Operating expense:
Cost of product sales	480,076	331,227	1,329,131	714,284
Research and development	8,736	43,775	26,982	47,667
Sales and marketing	1,626,630	1,972,155	4,869,717	2,257,166
General and administrative	1,321,001	1,779,048	4,207,899	4,012,357
Total operating expense	3,436,443	4,126,205	10,433,729	7,031,474
Loss from operations	(1,215,600)	(2,244,076)	(3,996,939)	(3,904,362)
Other income (expense):
Interest expense	(104,276)	(3,719,200)	(771,885)	(5,970,450)
Loss on extinguishment of debt	(89,341)	0	(394,169)	0
Other income (expense), net	(4,800)	(37)	(5,622)	1,839
Fair value adjustment for contingent consideration	69,305	186,813	195,459	164,479
Change in fair value of derivative liabilities	16,055	1,350,688	(32,138)	(632,627)
Total other expense, net	(113,057)	(2,181,736)	(1,008,355)	(6,436,759)
Loss before provision for income taxes	(1,328,657)	(4,425,812)	(5,005,294)	(10,341,121)
Provision for income taxes	0	0	3,200	0
Net loss	$ (1,328,657)	$ (4,425,812)	$ (5,008,494)	$ (10,341,121)
Net loss per share of common stock – basic and diluted	$ (0.01)	$ (0.04)	$ (0.03)	$ (0.12)
Weighted average number of shares of common stock outstanding – basic and diluted	161,587,934	104,972,645	152,325,196	86,498,234

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (5,008,494)	$ (10,341,121)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	8,258	9,431
Allowance for doubtful accounts	5,090	918
Common stock, restricted stock units and stock options issued to employees, board of directors and consultants for compensation and services	997,030	1,889,837
Loss on extinguishment of debt	394,169	0
Fair value of embedded conversion feature in convertible debentures in excess of allocated proceeds	0	2,756,899
Change in fair value of contingent consideration	(195,459)	(164,479)
Change in fair value of derivative liabilities	32,138	632,627
Amortization of debt discount	687,598	2,997,061
Amortization of intangible assets	472,675	513,767
Changes in operating assets and liabilities, net of acquisition amounts:
Accounts receivable	959	51,304
Prepaid expense and other current assets	177,297	(450,394)
Inventories	(40,199)	(142,329)
Accounts payable and accrued expenses	506,007	928,044
Accrued compensation	433,498	581,066
Accrued interest payable	(6,094)	10,976
Deferred revenue and customer deposits	(11,000)	(13,079)
Net cash used in operating activities	(1,546,527)	(739,472)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of property & equipment	(10,131)	(6,565)
Payment on contingent consideration	0	(150,000)
Net cash used in investing activities	(10,131)	(156,565)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of line of credit convertible debenture – related party	0	(409,192)
Proceeds from short-term loans payable	0	21,800
Payments on short-term loans payable	(7,199)	(252,151)
Proceeds from notes payable and convertible debentures	300,000	3,074,000
Payments on notes payable	(214,000)	(384,916)
Proceeds from stock option and warrant exercises	4,879	310,140
Financing costs in connection with convertible debentures	0	(40,000)
Proceeds from sale of common stock and warrants, net of offering costs	3,307,773	0
Payments on convertible debentures	(1,222,422)	(25,000)
Prepayment penalty on extinguishment of convertible debentures	(127,247)	0
Net cash provided by financing activities	2,041,784	2,294,681
Net change in cash	485,126	1,398,644
Cash at beginning of period	829,933	55,901
Cash at end of period	1,315,059	1,454,545
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	5,600	0
Cash paid for interest	89,931	205,456
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING & FINANCING ACTIVITIES:
Common stock issued for conversion of convertible debentures and accrued interest	577,835	2,935,900
Reclassification of the fair value of the embedded conversion features from derivative liability to additional paid-in capital upon conversion	203,630	2,962,666
Relative fair value of common stock issued in connection with notes payable recorded as debt discount	99,386	93,964
Proceeds from note payable paid to seller in connection with acquisition	0	300,000
Financing costs paid with proceeds from note payable	0	7,500
Cashless exercise of warrants	0	3,385
Fair value of the contingent consideration for acquisition	0	314,479
Reclassification of the fair value of the warrants from derivative liability to additional paid-in capital upon cashless exercise	0	518,224
Relative fair value of warrants issued in connection with convertible debentures recorded as debt discount	0	445,603
Relative fair value of common stock subscribed but unissued in connection with convertible debentures recorded as debt discount	0	1,127,225
Fair value of embedded conversion feature derivative liabilities recorded as debt discount	0	687,385
Fair value of warrants issued to placement agents in connection with convertible debentures recorded as debt discount	0	357,286
Fair value of non-forfeitable common stock issued to consultant recorded as prepaid expense and other current assets	0	135,540
Fair value of non-forfeitable common stock issued to consultant included in accounts payable and accrued expense	360,000	540,000
Issuance of shares of common stock for vested restricted stock units	92	19,229
Fair value of common stock issued for prepayment of future royalties due under the CRI License Agreement included in prepaid expense and other current assets	44,662	0
Fair value of beneficial conversion feature on line of credit convertible debenture – related party	0	3,444
Proceeds from short-term loan payable for payment of D&O insurance premium	$ 64,789	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Organization Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus”, “we”, “our”, “us” or the “Company”) is a Nevada formed, San Diego, California-based emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. We generate revenue from 22 commercial products in the United States, including six of these commercial products in multiple countries around the world through our commercial partners. Our commercial product portfolio includes (a) Beyond Human® Testosterone Booster, (b) Beyond Human® Growth Agent, (c) Zestra® to increase female arousal and desire, (d) EjectDelay® for premature ejaculation, (e) Sensum+® for reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) Androferti® to support overall male reproductive health and sperm quality, (i) RecalMax™ for cognitive brain health, (j) Beyond Human® Green Coffee Extract, (k) Beyond Human® Vision Formula, (l) Beyond Human® Blood Sugar, (m) Beyond Human® Colon Cleanse, (n) Beyond Human® Ketones, (o) Beyond Human® Krill Oil, (p) Beyond Human® Omega 3 Fish Oil, (q) UriVarx™ for bladder health, (r) ProstaGorx™ for prostate health, (s) AllerVarx ™ ™, Pipeline Products FlutiCare™ (fluticasone propionate nasal spray) Xyralid ™ . Urocis ™ XR AndroVit ™ In addition to the above listed product pipeline, we are continuously looking to add additional drugs, supplements and medical devices to our pipeline. Basis of Presentation and Principles of Consolidation The condensed consolidated balance sheet as of December 31, 2016, which has been derived from audited consolidated financial statements, and these unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc., Semprae Laboratories, Inc. (“Semprae”) and Novalere, Inc. (“Novalere”). All material intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016. Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The results for the period ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2017 or for any future period. Certain items have been reclassified to conform to the current year presentation. Use of Estimates The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include the allowance for doubtful accounts, sales returns and chargebacks, realizability of inventories, valuation of deferred tax assets, goodwill and intangible assets, valuation of contingent acquisition consideration, recoverability of long-lived assets and goodwill, fair value of derivative liabilities and the valuation of equity-based instruments and beneficial conversion features. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. Liquidity Our operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of our common stock and revenue generated from our products domestically and internationally by our partners. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of September 30, 2017, we had an accumulated deficit of $34,144,243 and a working capital deficit of $1,239,906. In March 2017, we raised net cash proceeds of $3,307,773 from the sale of common stock and warrants in a registered public offering (see Note 7) and, in October 2017, September 2017, January 2017 and December 2016, we raised $1,300,000 in gross proceeds from the issuance of notes payable to four investors (see Notes 5 and 10). We have also issued equity instruments in certain circumstances to pay for services from vendors and consultants. As of September 30, 2017, we had $1,315,059 in cash. During the nine months ended September 30, 2017, we had net cash used in operating activities of $1,546,527. We expect that our existing capital resources, the proceeds received from the issuance of notes payable in October 2017 totaling $500,000 (see Note 10), revenue from sales of our products and upcoming sales milestone payments from the commercial partners signed for our products will be sufficient to allow us to continue our operations, commence the product development process and launch selected products through at least the next 12 months. In addition, our CEO, who is also a significant shareholder, has deferred the remaining payment of his salary earned through June 30, 2016 totaling $1,531,904 for at least the next 12 months. Our actual needs will depend on numerous factors, including timing of introducing our products to the marketplace, our ability to attract additional international distributors for our products and our ability to in-license in non-partnered territories and/or develop new product candidates. Although no assurances can be given, we currently intend to raise additional capital through the sale of debt or equity securities to provide additional working capital, pay for further expansion and development of our business, and to meet current obligations. Such capital may not be available to us when we need it or on terms acceptable to us, if at all. Fair Value Measurement Our financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, derivative liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair values of the warrant derivative liabilities and embedded conversion feature derivative liabilities are based upon the Black Scholes Option Pricing Model (“Black-Scholes”) and the Path-Dependent Monte Carlo Simulation Model calculations, respectively, and are a Level 3 measurement (see Note 8). The fair value of the contingent acquisition consideration is based upon the present value of expected future payments under the terms of the agreements and is a Level 3 measurement (see Note 3). Based on borrowing rates currently available to us, the carrying values of the notes payable approximate their respective fair values. We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: ● Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access at the measurement date. ● Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly. ● Level 3 measurements are unobservable inputs. Concentration of Credit Risk, Major Customers and Segment Information Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of sales of Zestra® to U.S. based retailers and Ex-U.S. partners. We also require a percentage of payment in advance for product orders with our larger partners. We perform ongoing credit evaluations of our customers and generally do not require collateral. Revenues consist primarily of product sales and licensing rights to market and commercialize our products. We have no customers that accounted for 10% or more of our total net revenue during the three and nine months ended September 30, 2017 and 2016 and three customers accounted for 76% and 62% of total net accounts receivable as of September 30, 2017 and December 31, 2016, respectively. Over 95% of our sales are currently within the United States and Canada. The balance of the sales are to various other countries, none of which is 10% or greater. We operate our business on the basis of a single reportable segment, which is the business of delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. Our chief operating decision-maker is the Chief Executive Officer, who evaluates us as a single operating segment. Revenue Recognition and Deferred Revenue We generate revenue from product sales and the licensing of the rights to market and commercialize our products. We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition Product Sales License Revenue Milestone Method Sales Allowances We accrue for product returns, volume rebates and promotional discounts in the same period the related sale is recognized. Our product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. We estimate our volume rebates and promotional discounts accrual based on its estimates of the level of inventory of our products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by our customers. In all cases, judgment is required in estimating these reserves. Actual claims for rebates and returns and promotional discounts could be materially different from the estimates. We provide a customer satisfaction warranty on all of our products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated. The estimated reserve for sales returns and allowances, which is included in accounts payable and accrued expense, was approximately $44,000 and $61,000 at September 30, 2017 and December 31, 2016, respectively. Advertising Expense Advertising costs, which primarily includes print and online media advertisements, are expensed as incurred and are included in sales and marketing expense in the accompanying condensed consolidated statements of operations. Advertising costs were approximately $1,350,000 and $1,424,000 and $3,961,000 and $1,604,000 for the three and nine months ended September 30, 2017 and 2016, respectively. Debt Extinguishment Any gain or loss associated with debt extinguishment is recorded in the period in which the debt is considered extinguished. Third party fees incurred in connection with a debt restructuring accounted for as an extinguishment are capitalized. Fees paid to third parties associated with a term debt restructuring accounted for as a modification are expensed as incurred. Third party and creditor fees incurred in connection with a modification to a line of credit or revolving debt arrangements are considered to be associated with the new arrangement and are capitalized. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested but deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the three and nine months ended September 30, 2017 and 2016, basic net loss per share is the same as diluted net loss per share as a result of our common stock equivalents being anti-dilutive. See Note 7 for more details. Recent Accounting Pronouncements In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting Compensation - Stock Compensation ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. As a result of the adoption of this ASU as of January 1, 2017, we have made an entity-wide accounting policy election to account for forfeitures when they occur. There is no cumulative-effect adjustment as a result of the adoption of this ASU as our estimated forfeiture rate prior to adoption of this ASU was 0%. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. We plan to adopt the standard on January 1, 2018. We currently believe that once we do adopt this standard, we will use the modified retrospective approach. Under the modified approach, an entity recognizes “the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application” (revenue in periods presented in the consolidated financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the consolidated financial statement line items and respective amounts directly affected by the standard’s application. While we are still currently assessing the impact of the new standard, our revenue is primarily generated from the sale of finished product to customers. Those sales predominantly contain a single delivery element and revenue is recognized at a single point in time when ownership, risks and rewards transfer. The timing of revenue recognition for these product sales are not materially impacted by the new standard. However, we are utilizing a comprehensive approach to assess the impact of the guidance on our current contract portfolio by reviewing our current accounting policies and practices to identify potential differences that would result from applying the new requirements to our revenue contracts, including evaluation of performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and accounting treatment of costs to obtain and fulfill contracts. We continue to make significant progress on the potential impact on our accounting policies and internal control processes including system readiness. In addition, we will update certain disclosures, as applicable, included in our filings pursuant to the Securities Exchange Act of 1934, as amended, to meet the requirements of the new guidance. In February 2016, the FASB issued ASU 2016-02, Leases

LICENSE AGREEMENTS

LICENSE AGREEMENTS	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSE AGREEMENTS	CRI In-License Agreement On April 19, 2013, the Company and Centric Research Institute (“CRI”) entered into an asset purchase agreement (the “CRI Asset Purchase Agreement”) pursuant to which we acquired: ● All of CRI’s rights in past, present and future Sensum+® product formulations and presentations, and ● An exclusive, perpetual license to commercialize Sensum+® products in all territories except for the United States. On June 9, 2016, the Company and CRI amended the CRI Asset Purchase Agreement (“Amended CRI Asset Purchase Agreement”) to provide us commercialization rights for Sensum+® in the U.S. through our Beyond Human® marketing platform through December 31, 2016. On January 1, 2017, the Company and CRI agreed to extend the term of the Amended CRI Asset Purchase Agreement to December 31, 2017. In connection with the extension, we issued restricted shares of common stock totaling 225,000 to CRI as a prepayment of royalties due on net profit of Sensum+® in the U.S. in 2017. The royalty prepayment amount is $44,662 as the number of shares of common stock issued was based on the closing price of our common stock on December 30, 2016. If CRI does not earn royalties larger than the prepaid amount of $44,662 in 2017, the term of the Amended CRI Asset Purchase Agreement is automatically extended one additional year to December 31, 2018. The CRI Asset Purchase Agreement also requires us to pay to CRI up to $7.0 million in cash milestone payments based on first achievement of annual Ex-U.S. net sales targets plus a royalty based on annual Ex-U.S. net sales. The obligation for these payments expires on April 19, 2023 or the expiration of the last of CRI’s patent claims covering the product or its use outside the U.S., whichever is sooner. No sales milestone obligations have been met and no royalties are owed to CRI under this agreement during the three and nine months ended September 30, 2017 and 2016. In consideration for the Amended CRI Asset Purchase Agreement, we are required to pay CRI a percentage of the monthly net profit, as defined in the agreement, from our sales of Sensum+® in the U.S. through our Beyond Human® marketing platform. During the three and nine months ended September 30, 2017 and 2016, no amounts have been earned by CRI under the Amended CRI Asset Purchase Agreement. Densmore Pharmaceutical International Agreement On April 24, 2017, we entered into an exclusive ten-year license agreement with Densmore Pharmaceutical International, a Monaco company (“Densmore”), under which we granted to Densmore an exclusive license to market and sell our topical treatment for Female Sexual Interest/Arousal Disorder (“FSI/AD”) Zestra® in France and Belgium. Under the agreement, we received a non-refundable upfront payment of $7,500 which was recognized as revenue in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2017. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future minimum order quantities. Densmore is obligated to order certain minimum annual quantities of Zestra® at a pre-negotiated transfer price per unit during the term of the agreement. During the three and nine months ended September 30, 2017, we recognized revenue for the sale of products related to this agreement of $100,341. In July 2017, we entered into an amendment to the agreement with Densmore to expand the product territory to Singapore and Vietnam. Luminarie Pty Ltd. Agreement On May 16, 2017, we entered into an exclusive ten-year license agreement with Luminarie Pty Ltd., a Australia company (“Luminarie”), under which we granted to Luminarie an exclusive license to market and sell our topical treatment for FSI/AD Zestra® and Zestra Glide® in Australia, New Zealand and the Philippines. Luminarie received approval for Zestra® as a Class I Medical Device in Australia in July 2017 and New Zealand in September 2017. Luminarie is obligated to order certain minimum annual quantities of Zestra® and Zestra Glide® at a pre-negotiated transfer price per unit during the term of the agreement. During the three and nine months ended September 30, 2017, we did not recognize any revenue for the sale of products related to this agreement. LI USA Co. Agreement On November 9, 2016, we entered into an exclusive ten-year license agreement with J&H Co. LTD, a South Korea company (“J&H”), under which we granted to J&H an exclusive license to market and sell our topical treatment for Female Sexual Interest/Arousal Disorder (“FSI/AD”) Zestra® and Zestra Glide® in South Korea. Under the agreement, J&H is obligated to order minimum annual quantities of Zestra® and Zestra Glide® totaling $2.0 million at a pre-negotiated transfer price per unit. The minimum annual order quantities by J&H are to be made over a 12-month period following the approval of the product by local authorities and beginning upon the completion of the first shipment of product. Our partner recently received the approval to import the product and placed its first order in March 2017. During the three and nine months ended September 30, 2017, we recognized $0 and $60,000 in revenue for the sale of products related to this agreement. On October 26, 2017, the exclusive license and distributor rights under this agreement were assigned to LI USA Co., a U.S. company (“LI USA”), from J&H and LI USA is now the distributor under this agreement. LI USA is controlled by the same original owners as J&H. All terms and conditions of the original agreement remain intact. Sothema Laboratories Agreement On September 23, 2014, we entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan publicly traded company (“Sothema”), under which we granted to Sothema an exclusive license to market and sell Zestra® (based on the latest Canadian approval of the indication) and Zestra Glide® in several Middle Eastern and African countries (collectively the “Territory”). Under the agreement, we received an upfront payment of $200,000 and are eligible to receive additional consideration upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory, plus a pre-negotiated transfer price per unit. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future sales-based milestones. As the sales-based milestones do not meet the definition of a milestone under ASC 605-28, we will recognize the revenue from the milestone payments when the cumulative supplied units’ volume is met. During the three and nine months ended September 30, 2017 and 2016, we recognized $0 and $666 and $0 and $12,229, respectively, in net revenue for the sales of products related to this agreement, and no revenue was recognized for the sales-based milestones of the agreement. Orimed Pharma Agreement On September 18, 2014, we entered into a twenty-year exclusive license agreement with Orimed Pharma (“Orimed”), an affiliate of JAMP Pharma, under which we granted to Orimed an exclusive license to market and sell in Canada Zestra®, Zestra Glide®, our topical treatment for premature ejaculation EjectDelay® and our product Sensum+® to increase penile sensitivity. Under the agreement, we received an upfront payment of $100,000 and are eligible to receive additional consideration upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus double-digit tiered royalties based on Orimed’s cumulative net sales in Canada. We believe the amount of the upfront payment received is reasonable compared to the amounts to be received upon obtainment of future sales-based milestones. As the sales-based milestones do not meet the definition of a milestone under ASC 605-28, we will recognize the revenue from the milestone payments when the cumulative gross sales volume is met. We will recognize the revenue from the royalty payments on a quarterly basis when the cumulative net sales have been met. During the three and nine months ended September 30, 2017 and 2016, under this agreement we recognized $11,230 and $40,233 and $32,143 and $49,376, respectively, in net revenue for the sales of products and no revenue was recognized for the sales-based milestones.

BUSINESS AND ASSET ACQUISITIONS

BUSINESS AND ASSET ACQUISITIONS	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
BUSINESS AND ASSET ACQUISITIONS	Acquisition of Novalere in 2015 On February 5, 2015 (the “Closing Date”), Innovus, Innovus Pharma Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Innovus (“Merger Subsidiary I”), Innovus Pharma Acquisition Corporation II, a Delaware corporation and a wholly-owned subsidiary of Innovus (“Merger Subsidiary II”), Novalere FP, Inc., a Delaware corporation (“Novalere FP”) and Novalere Holdings, LLC, a Delaware limited liability company (“Novalere Holdings”), as representative of the shareholders of Novalere (the “Novalere Stockholders”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Subsidiary I merged into Novalere and then Novalere merged with and into Merger Subsidiary II (the “Merger”), with Merger Subsidiary II surviving as a wholly-owned subsidiary of Innovus. Pursuant to the articles of merger effectuating the Merger, Merger Subsidiary II changed its name to Novalere, Inc. With the Merger, we acquired the worldwide rights to market and sell the FlutiCare™ brand (fluticasone propionate nasal spray) and the related third-party manufacturing agreement for the manufacturing of FlutiCare™ (“Acquisition Manufacturer”) from Novalere FP. The OTC Abbreviated New Drug Application (“ANDA”) for fluticasone propionate nasal spray was filed at the end of 2014 by our third-party manufacturer and partner, who is currently selling the prescription version of the drug, with the FDA and the OTC ANDA is still subject to FDA approval. An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. A prescription ANDA (“RX ANDA”) is for a generic version of a prescription pharmaceutical and an OTC ANDA is for a generic version of an OTC pharmaceutical. Due to the delay in approval of the Acquisition Manufacturer’s OTC ANDA by the FDA, in May 2017, we announced a commercial relationship with a different third-party manufacturer (West-Ward Pharmaceuticals International Limited or “WWPIL”) who has an FDA approved OTC ANDA for fluticasone propionate nasal spray under which they have agreed to manufacture our FlutiCare™ OTC product for sale in the U.S. (see Note 9). We currently still anticipate that the OTC ANDA filed in November 2014 by the Acquisition Manufacturer with the FDA may be approved in 2017. As we hold the worldwide rights to market and sell FlutiCare™ under the manufacturing agreement with the Acquisition Manufacturer, we believe the agreement with the Acquisition Manufacturer will still provide us with the opportunity to market and sell FlutiCare™ ex-U.S. and, if the OTC ANDA is approved by the FDA, a second source of supply within the U.S., if ever needed. The Novalere Stockholders are entitled to receive, if and when earned, earn-out payments (the “Earn-Out Payments”). For every $5.0 million in Net Revenue (as defined in the Merger Agreement) realized from the sales of FlutiCare™ through the manufacturing agreement with the Acquisition Manufacturer, the Novalere Stockholders will be entitled to receive, on a pro rata basis, $500,000, subject to cumulative maximum Earn-Out Payments of $2.5 million. The Novalere Stockholders are only entitled to the Earn-Out Payments from the Acquisition Manufacturer’s OTC ANDA under review by the FDA and have no earn-out rights to the sales of FlutiCare™ supplied by WWPIL under the commercial agreement entered into in May 2017. During the three and nine months ended September 30, 2017, there was a decrease in the estimated fair value of the remaining 138,859 ANDA consideration shares totaling $2,400 and $22,107 which is included in fair value adjustment for contingent consideration in the accompanying condensed consolidated statement of operations. The remaining 138,859 ANDA consideration shares not issuable yet will be issued upon FDA approval of the ANDA filed by the Acquisition Manufacturer and the estimated fair value of such remaining shares of $10,109 is included in contingent consideration in the accompanying condensed consolidated balance sheet at September 30, 2017. There was no change to the estimated fair value of the future earn-out payments of $1,248,124 during the three and nine months ended September 30, 2017 and there was no change to the estimated fair value of the contingent consideration during the three and nine months ended September 30, 2016. Purchase of Semprae Laboratories, Inc. in 2013 On December 24, 2013 (the “Semprae Closing Date”), we, through Merger Sub, obtained 100% of the outstanding shares of Semprae in exchange for the issuance of 3,201,776 shares of our common stock, which shares represented 15% of our total issued and outstanding shares as of the close of business on the Closing Date, whereupon Merger Sub was renamed Semprae Laboratories, Inc. We agreed to pay the former shareholders an annual royalty (“Royalty”) equal to 5% of the net sales from Zestra® and Zestra Glide® and any second generation products derived primarily therefrom (“Target Products”) up until the time that a generic version of such Target Product is introduced worldwide by a third party. The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the consolidated statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. During the three and nine months ended September 30, 2017 and 2016, no amounts have been paid under this arrangement. The fair value of the expected royalties to be paid was decreased by $66,905 and $0 and $173,352 and $0 during the three and nine months ended September 30, 2017 and 2016, respectively, which is included in the fair value adjustment for contingent consideration in the accompanying condensed consolidated statements of operations. The fair value of the contingent consideration was $232,225 and $405,577 at September 30, 2017 and December 31, 2016, respectively, based on the new estimated fair value of the consideration.

ASSETS AND LIABILITIES

ASSETS AND LIABILITIES	9 Months Ended
	Sep. 30, 2017
ASSETS
ASSETS AND LIABILITIES	Inventories Inventories consist of the following: September 30, December 31, 2017 2016 Raw materials and supplies $ 194,895 $ 85,816 Work in process 62,786 48,530 Finished goods 382,374 465,510 Total $ 640,055 $ 599,856 Intangible Assets Amortizable intangible assets consist of the following: September 30, 2017 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 (116,408 ) $ 301,189 7 – 15 Customer Contracts 611,119 (234,262 ) 376,857 10 Sensum+® License (from CRI) 234,545 (101,600 ) 132,945 10 Vesele® Trademark 25,287 (9,418 ) 15,869 8 Beyond Human® Website and Trade Name 222,062 (62,360 ) 159,702 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,238,515 ) 3,442,485 10 Other Beyond Human® Intangible Assets 4,730 (3,205 ) 1,525 1 – 3 $ 6,196,340 $ (1,765,768) $ 4,430,572 December 31, 2016 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (91,201 ) $ 326,396 7 – 15 Customer Contracts 611,119 (188,428 ) 422,691 10 Sensum+® License (from CRI) 234,545 (84,009 ) 150,536 10 Vesele® Trademark 25,287 (7,047 ) 18,240 8 Beyond Human® Website and Trade Name 222,062 (32,821 ) 189,241 5 – 10 Novalere Manufacturing Contract 4,681,000 (887,440 ) 3,793,560 10 Other Beyond Human® Intangible Assets 4,730 (2,147 ) 2,583 1 – 3 Total $ 6,196,340 $ (1,293,093 ) $ 4,903,247 Amortization expense for the three and nine months ended September 30, 2017 and 2016 was $157,477 and $178,082 and $472,675 and $513,767, respectively. The following table summarizes the approximate expected future amortization expense as of September 30, 2017 for intangible assets: Remainder of 2017 $ 157,000 2018 630,000 2019 629,000 2020 629,000 2021 600,000 2022 592,000 Thereafter 1,194,000 $ 4,431,000 Prepaid Expense and Other Current Assets Prepaid expense and other current assets consist of the following: September 30, December 31, 2017 2016 Prepaid insurance $ 75,522 $ 69,976 Prepaid inventory 80,208 20,750 Merchant net settlement reserve receivable - 221,243 Prepaid consulting and other expense 64,825 21,094 Prepaid CRI royalties (see Note 2) 44,662 - Prepaid consulting and other service stock-based compensation expense (see Note 7) - 530,601 Total $ 265,217 $ 863,664 Accounts Payable and Accrued Expense Accounts payable and accrued expense consist of the following: September 30, December 31, 2017 2016 Accounts payable $ 1,105,875 $ 647,083 Accrued credit card balances 43,614 31,654 Accrued royalties 129,022 73,675 Sales returns and allowances 44,051 60,853 Accrual for stock to be issued to consultants (see Note 7) - 360,000 Accrued other 33,495 36,785 Total $ 1,356,057 $ 1,210,050

NOTES PAYABLE AND DEBENTURES -

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES	9 Months Ended
	Sep. 30, 2017
Notes Payable [Abstract]
NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES	Short-Term Loan Payable The short-term loan payable consists of the financing of our director and officer insurance premium with a third party totaling $64,789. Under the financing agreement we are required to make nine monthly installment payments of $7,371. The balance outstanding as of September 30, 2017 is $57,590. Notes Payable The following table summarizes the outstanding notes payable at September 30, 2017 and December 31, 2016: 2017 2016 Notes payable: February 2016 Note Payable $ 133,997 $ 347,998 December 2016 and September 2017 Notes Payable 660,000 550,000 Total notes payable 793,997 897,998 Less: Debt discount (71,531 ) (216,871 ) Carrying value 722,466 681,127 Less: Current portion (722,466 ) (626,610 ) Notes payable, net of current portion $ - $ 54,517 The following table summarizes the future minimum payments as of September 30, 2017 for the notes payable: Remainder of 2017 $ 574,012 2018 219,985 $ 793,997 February 2016 Note Payable On February 24, 2016, the Company and SBI Investments, LLC, 2014-1 (“SBI”) entered into an agreement in which SBI loaned us gross proceeds of $550,000 pursuant to a purchase agreement, 20% secured promissory note and security agreement (“February 2016 Note Payable”), all dated February 19, 2016 (collectively, the “Finance Agreements”), to purchase substantially all of the assets of Beyond Human®. We began to pay principal and interest on the February 2016 Note Payable on a monthly basis beginning on March 19, 2016 for a period of 24 months and the monthly mandatory principal and interest payment amount thereunder is $28,209. The monthly amount shall be paid by us through a deposit account control agreement with a third-party bank in which SBI shall be permitted to take the monthly mandatory payment amount from all revenue received by us from the Beyond Human® assets in the transaction. The maturity date for the February 2016 Note Payable is February 19, 2018. The February 2016 Note Payable is secured by SBI through a first priority secured interest in all of the Beyond Human® assets acquired by us in the transaction including all revenue received by us from these assets. December 2016, January 2017 and September 2017 Notes Payable On December 5, 2016, January 19, 2017 and September 20, 2017, we entered into a securities purchase agreement with three unrelated third-party investors in which the investors loaned us gross proceeds of $500,000 in December 2016, $150,000 in January 2017 and $150,000 in September 2017 pursuant to a 5% promissory note (“2016 and 2017 Notes Payable”). The notes have an Original Issue Discount (“OID”) of $80,000 and require payment of $880,000 in principal upon maturity. The 2016 and 2017 Notes Payable bear interest at the rate of 5% per annum and the principal amount and interest are payable at maturity on October 4, 2017, November 18, 2017 and May 20, 2018 for those received in December 2016, January 2017 and September 2017, respectively. In connection with the 2016 and 2017 Notes Payable, we issued the investors restricted shares of common stock totaling 1,111,111 in December 2016, 330,000 in January 2017 and 895,000 in September 2017. The fair value of the restricted shares of common stock issued was based on the market price of our common stock on the date of issuance of the 2016 and 2017 Notes Payable (see Note 7). The allocation of the proceeds received to the restricted shares of common stock based on their relative fair value and the OID resulted in us recording a debt discount of $182,203 in December 2016, $44,217 in January 2017 and $55,169 in September 2017. The discount is being amortized to interest expense using the effective interest method over the term of the 2016 and 2017 Notes Payable. In August and September 2017, we entered into a securities exchange agreement with certain of the 2016 and 2017 Notes Payable holders. In connection with the securities exchange agreements, we issued a total of 2,840,316 shares of common stock in exchange for the settlement of principal and interest due under the 2016 and 2017 Notes Payable totaling $227,225. The fair value of the shares of common stock issued was based on the market price of our common stock on the date of the securities exchange agreements (see Note 7). Due to the settlement of the principal and interest balance of $227,225 into shares of common stock, the transaction was recorded as a debt extinguishment and the fair value of the shares of common stock issued in excess of the settled principal and interest balance totaling $72,166 and the remaining unamortized debt discount as of the date of settlement of $17,175 were recorded as a loss on debt extinguishment in the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2017. In October 2017, certain of the 2016 and 2017 Notes Payable holders with outstanding principal balances totaling $495,000 elected to settle their outstanding principal and interest balances in exchange for shares of common stock (see Note 10). Interest Expense We recognized interest expense on notes payable of $17,750 and $42,652 and $64,463 and $131,567 for the three and nine months ended September 30, 2017 and 2016, respectively. Amortization of the debt discount to interest expense during the three and nine months ended September 30, 2017 and 2016 totaled $86,250 and $938 and $257,550 and $96,309, respectively. Convertible Debentures 2016 Financing The following table summarizes the outstanding 2016 convertible debentures at September 30, 2017 and December 31, 2016: 2017 2016 Convertible debentures $ - $ 1,559,922 Less: Debt discount - (845,730 ) Carrying value - 714,192 Less: Current portion - (714,192 ) Convertible debentures, net of current portion $ - $ - In the second and third quarter of 2016, we entered into Securities Purchase Agreements with eight accredited investors (the “Investors”), pursuant to which we received aggregate gross proceeds of $3.0 million (net of OID) pursuant to which we sold: Nine convertible promissory notes of the Company totaling $3,303,889 (each a “2016 Note” and collectively the “2016 Notes”) (the 2016 Notes were sold at a 10% OID and we received an aggregate total of $2,657,500 in funds thereunder after debt issuance costs of $342,500). The 2016 Notes and accrued interest were convertible into shares of our common stock at a conversion price of $0.25 per share, with certain adjustment provisions. The maturity date of the 2016 Notes issued on June 30, 2016 and July 15, 2016 was July 30, 2017 and the maturity date of the 2016 Notes issued on July 25, 2016 was August 25, 2017. The 2016 Notes bore interest on the unpaid principal amount at the rate of 5% per annum from the date of issuance until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. We had the ability to prepay the 2016 Notes at any time on the terms set forth in the 2016 Notes at the rate of 110% of the then outstanding balance of the 2016 Notes. The fair value of the restricted shares of common stock issued to Investors in 2016 was based on the market price of our common stock on the date of issuance of the 2016 Notes. The allocation of the proceeds to the warrants and restricted shares of common stock based on their relative fair values resulted in us recording a debt discount. We also determined that the embedded conversion features in the 2016 Notes were a derivative instrument which was required to be bifurcated from the debt host contract and recorded at fair value as a derivative liability. The fair value of the embedded conversion features was determined using a Path-Dependent Monte Carlo Simulation Model (see Note 8 for assumptions used to calculate fair value). The initial fair value of the embedded conversion features was recorded as a debt discount with the amount in excess of the proceeds allocated to the debt, after the allocation of debt proceeds to the debt issuance costs, being immediately expensed and recorded as interest expense in 2016. During the nine months ended September 30, 2017, certain of the 2016 Notes holders elected to convert principal and interest outstanding of $350,610 into 1,402,440 shares of common stock at a conversion price of $0.25 per share (see Note 7). As a result of the conversion of the principal and interest balance into shares of common stock, the fair value of the embedded conversion feature derivative liabilities of $203,630 on the date of conversion was reclassified to additional paid-in capital (see Note 8) and the amortization of the debt discount was accelerated for the amount converted and recorded to interest expense during the nine months ended September 30, 2017. As a result of the completion of a public equity offering in March 2017 (see Note 7), we were required to prepay the outstanding principal and accrued interest balance of the 2016 Notes with the cash proceeds received from such offering. The outstanding principal and accrued interest balance of $1,272,469 was repaid in March 2017, as well as, a 10% prepayment penalty of $127,247. Due to the acceleration of repayment of the 2016 Notes as a result of the public equity offering, the transaction was recorded as a debt extinguishment and the 10% prepayment penalty of $127,247 and the remaining unamortized debt discount as of the date of repayment of $415,682 were recorded as a loss on debt extinguishment in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2017. The repayment of the outstanding principal and accrued interest balance of the 2016 Notes resulted in the extinguishment of the embedded conversion feature derivative liability and thus the fair value as of the date of repayment of $238,101 was recorded as a reduction to the loss on debt extinguishment in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2017. Interest Expense We recognized interest expense on the 2016 Notes for the nine months ended September 30, 2017 of $19,544. The debt discount recorded for the 2016 Notes were being amortized as interest expense over the term of the 2016 Notes using the effective interest method. Total amortization of the debt discount on the 2016 Notes to interest expense for the nine months ended September 30, 2017 was $430,048.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
RELATED PARTY TRANSACTIONS	Accrued Compensation – Related Party Accrued compensation includes accruals for employee wages, vacation pay and target-based bonuses. The components of accrued compensation as of September 30, 2017 and December 31, 2016 are as follows: September 30, 2017 December 31, 2016 Wages $ 1,431,686 $ 1,455,886 Vacation 323,163 261,325 Bonus 843,262 449,038 Payroll taxes on the above 134,980 133,344 Total 2,733,091 2,299,593 Classified as long-term (1,531,904 ) (1,531,904 ) Accrued compensation $ 1,201,187 $ 767,689 Accrued employee wages at September 30, 2017 and December 31, 2016 are entirely related to wages owed to our President and Chief Executive Officer. Under the terms of his employment agreement, wages are to be accrued but no payment made for, so long as payment of such salary would jeopardize our ability to continue as a going concern. The President and Chief Executive Officer started to receive payment of salary in July 2016. Our President and Chief Executive Officer has agreed to not receive payment on his remaining accrued wages and related payroll tax amounts within the next 12 months and thus the remaining balance is classified as a long-term liability. In April 2017, our Board of Directors approved for payment the accrued fiscal year 2016 bonus of $33,442 to our former Executive Vice President and Chief Financial Officer in accordance with his employment agreement and the bonus amount was paid upon his departure. The fiscal year 2016 bonus for our President and Chief Executive Officer has not yet been approved by our Board of Directors but is included in accrued compensation in the accompanying condensed consolidated balance sheets as of September 30, 2017 and December 31, 2016.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
STOCKHOLDERS’ EQUITY	Issuances of Common Stock Public Equity Offering On March 21, 2017, we completed a sale of common stock and warrants under a registered public offering. The gross proceeds to us from the offering were $3,850,000, before underwriting discounts and commissions and other offering expenses ($3,307,773 after underwriting discounts, commissions and expenses). The public offering price per share of common stock sold was $0.15. Each investor who purchased a share of common stock in the offering received a five-year warrant to purchase one share of common stock at an exercise price of $0.15 per share (“Series A Warrants”) and a one-year warrant to purchase one share of common stock at an exercise price of $0.15 per share (“Series B Warrants”). Under the terms of the offering, we issued 25,666,669 shares of common stock, Series A Warrants to purchase up to an aggregate of 25,666,669 shares of common stock and Series B Warrants to purchase up to an aggregate of 25,666,669 shares of common stock. The Series A Warrants and Series B Warrants are exercisable immediately. We allocated the net proceeds received of $3,307,773 to the shares of common stock, Series A Warrants and Series B Warrants sold in the offering based on their relative fair values. The fair value of the Series A Warrants and Series B Warrants was determined using Black-Scholes. Based on their relative fair values, we allocated net of proceeds of $1,593,233 to the shares of common stock, $1,075,995 to the Series A Warrants and $638,545 to the Series B Warrants. In connection with this offering, we issued to H.C. Wainwright & Co. (“HCW”), the underwriter in the offering, a warrant to purchase up to 1,283,333 shares of common stock and HCW received total cash consideration, including the reimbursement of public offering-related expenses, of $443,000. If such warrant is exercised, each share of common stock may be purchased at $0.1875 per share (125% of the price of the common stock sold in the offering), commencing on March 21, 2017 and expiring March 21, 2022. The fair value of the warrants issued to HCW totaled $129,755 and was determined using Black-Scholes. The fair value of the warrants was recorded as an offering cost but has no net impact to additional paid-in capital in stockholders’ equity in the accompanying condensed consolidated balance sheet. In connection with this offering, we incurred $99,227 in other offering costs that have been offset against the proceeds from this offering. Other Stock Issuances and Related Stock-Based Compensation On August 23, 2016, we entered into a consulting agreement with a third party pursuant to which we agreed to issue 1,600,000 restricted shares of common stock, payable in four equal installments, in exchange for services to be rendered over the agreement which ended on August 23, 2017. The shares were considered fully-vested and non-refundable at the execution of the agreement. In 2016, we issued 800,000 shares of common stock and during the nine months ended September 30, 2017, we issued a total of 800,000 shares of common stock under the agreement. The fair value of the shares issued during 2017 of $360,000 was based on the market price of our common stock on the date of agreement. During the three and nine months ended September 30, 2017, we recognized $105,000 and $465,000, respectively, in general and administrative expense in the accompanying condensed consolidated statements of operations. On September 1, 2016, we entered into a service agreement with a third party pursuant to which we agreed to issue, over the term of the agreement, 2,000,000 shares of common stock in exchange for services to be rendered. The agreement was extended on July 20, 2017 through December 31, 2017. In connection with the extension, we agreed to issue 1,200,000 shares of common stock in exchange for services to be rendered. We have terminated this agreement effective November 9, 2017. During the nine months ended September 30, 2017, we issued 1,270,000 shares under the agreement related to services provided and recognized the fair value of the shares issued of $187,315 in general and administrative expense in the accompanying condensed consolidated statement of operations. The 1,270,000 shares of common stock vested on the date of issuance and the fair value of the shares of common stock was based on the market price of our common stock on the date of vesting. There are 219,512 shares of common stock to be issued under this service agreement as of September 30, 2017. On November 17, 2016, we entered into a service agreement with a third party and in connection with the agreement issued 275,000 fully-vested shares for services to be provided over the term of the service agreement through May 17, 2017. The fair value of the shares issued of $69,575 was based on the market price of our common stock on the date of vesting. During the nine months ended September 30, 2017, we recognized $52,181 in general and administrative expense in the accompanying condensed consolidated statements of operations. On December 16, 2016, we amended a consulting agreement with a third party to extend the term of the agreement to June 16, 2017 and in connection with the amendment issued 80,000 fully-vested shares for services to be provided over the remaining term of the amended agreement. The fair value of the shares issued of $14,640 was based on the market price of our common stock on the date of vesting. On January 19, 2017, we further amended the agreement to expand the scope of service performed by the consultant and as a result issued an additional 78,947 shares of fully vested common stock for services to be provided through June 16, 2017. The fair value of the shares issued of $15,000 was based on the market price of our common stock on the date of vesting. During the nine months ended September 30, 2017, we recognized $28,420 in general and administrative expense in the accompanying condensed consolidated statements of operations. In January 2017, April 2017 and July 2017, we issued a total of 72,830 shares of common stock for services and recorded an expense of $5,000 and $9,000 for the three and nine months ended September 30, 2017, respectively, which is included in general and administrative expense in the accompanying condensed consolidated statements of operations. The 72,830 shares of common stock vested on the date of issuance and the fair value of the shares of common stock was based on the market price of our common stock on the date of vesting. In January 2017, we issued 225,000 shares of common stock to CRI pursuant to the Amended CRI Asset Purchase Agreement (see Note 2) for the prepayment of future royalties due on net profit of Sensum+® in the U.S. in 2017. The fair value of the restricted shares of common stock of $44,662 was based on the market price of our common stock on the date of issuance and is included in prepaid expense and other current assets in the accompanying condensed consolidated balance sheet at September 30, 2017. In January 2017 and September 2017, we issued 1,225,000 shares of restricted common stock to note holders in connection with their notes payable. The relative fair value of the shares of restricted common stock issued was determined to be $99,386 and was recorded as a debt discount (see Note 5). In March 2017, certain 2016 Notes holders elected to convert $350,610 in principal and interest into 1,402,440 shares of common stock (see Note 5). Upon conversion, the fair value of the embedded conversion feature derivative liability on the date of conversion was reclassified to additional paid-in capital (see Note 8). In March 2017 and July 2017, we issued shares of common stock totaling 71,500 upon the exercise of stock options for total cash proceeds of $4,879. In June 2017, we issued 92,000 shares of common stock in exchange for vested restricted stock units. In September 2017, certain 2016 and 2017 Notes Payable holders elected to exchange $227,225 in principal and interest for 2,840,316 shares of common stock (see Note 5). The fair value of the shares of common stock of $299,391 was based on the market price of our common stock on the date of issuance. 2013 Equity Incentive Plan We have issued common stock, restricted stock units and stock option awards to employees, non-executive directors and outside consultants under the 2013 Equity Incentive Plan (“2013 Plan”), which was approved by our Board of Directors in February of 2013. The 2013 Plan allows for the issuance of up to 10,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. As of September 30, 2017, 106,000 shares were available under the 2013 Plan. 2014 Equity Incentive Plan We have issued common stock, restricted stock units and stock options to employees, non-executive directors and outside consultants under the 2014 Equity Incentive Plan (“2014 Plan”), which was approved by our Board of Directors in November 2014. The 2014 Plan allows for the issuance of up to 20,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. As of September 30, 2017, 58,367 shares were available under the 2014 Plan. 2016 Equity Incentive Plan On March 21, 2016, our Board of Directors approved the adoption of the 2016 Equity Incentive Plan and on October 20, 2016 adopted the Amended and Restated 2016 Equity Incentive Plan (“2016 Plan”). The 2016 Plan was then approved by our stockholders in November 2016. The 2016 Plan allows for the issuance of up to 20,000,000 shares of our common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. The 2016 Plan includes an evergreen provision in which the number of shares of common stock authorized for issuance and available for future grants under the 2016 Plan will be increased each January 1 after the effective date of the 2016 Plan by a number of shares of common stock equal to the lesser of: (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, or (b) a number of shares of common stock set by our Board of Directors. In March 2017, our Board of Directors approved an increase of 5,663,199 shares of common stock to the shares authorized under the 2016 Plan in accordance with the evergreen provision in the 2016 Plan. As of September 30, 2017, 21,140,750 shares were available under the 2016 Plan. Stock Options For the nine months ended September 30, 2017 and 2016, the following weighted average assumptions were utilized for the calculation of the fair value of the stock options granted during the period using Black-Scholes: 2017 2016 Expected life (in years) 8.9 10.0 Expected volatility 215.4 % 227.8 % Average risk-free interest rate 2.27 % 1.71 % Dividend yield 0 % 0 % Grant date fair value $ 0.17 $ 0.17 The dividend yield of zero is based on the fact that we have never paid cash dividends and has no present intention to pay cash dividends. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the stock options. Expected life in years is based on the “simplified” method as permitted by ASC Topic 718. We believe that all stock options issued under its stock option plans meet the criteria of “plain vanilla” stock options. We use a term equal to the term of the stock options for all non-employee stock options. The risk-free interest rate is based on average rates for treasury notes as published by the Federal Reserve in which the term of the rates correspond to the expected term of the stock options. The following table summarizes the number of stock options outstanding and the weighted average exercise price: Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2016 237,500 $ 0.22 8.6 $ 14,293 Granted 37,000 0.17 - - Exercised (71,500 ) 0.07 - - Cancelled (124,000 ) 0.31 - - Forfeited - - - - Outstanding at September 30, 2017 79,000 $ 0.18 9.1 $ 468 Vested and Expected to Vest at September 30, 2017 79,000 $ 0.18 9.1 $ 468 The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding stock options and the quoted price of our common stock at September 30, 2017. During the three and nine months ended September 30, 2017 and 2016, the Company recognized stock-based compensation from stock options of $904 and $8,638 and $6,310 and $18,138, respectively. The intrinsic value of the stock options exercised during the nine months ended September 30, 2017 on the dates of exercise were $7,133. Restricted Stock Units The following table summarizes the restricted stock unit activity for the nine months ended September 30, 2017: Restricted Stock Units Outstanding at December 31, 2016 12,874,848 Granted 2,777,119 Exchanged (92,000 ) Cancelled (2,500,000 ) Outstanding at September 30, 2017 13,059,967 Vested at September 30, 2017 9,622,467 The vested restricted stock units at September 30, 2017 have not settled and are not showing as issued and outstanding shares of ours but are considered outstanding for earnings per share calculations. Settlement of these vested restricted stock units will occur on the earliest of (i) the date of termination of service of the employee or consultant, (ii) change of control of us, or (iii) 10 years from date of issuance. Settlement of vested restricted stock units may be made in the form of (i) cash, (ii) shares, or (iii) any combination of both, as determined by the board of directors and is subject to certain criteria having been fulfilled by the recipient. We calculate the fair value of the restricted stock units based upon the quoted market value of the common stock at the date of grant. The grant date fair value of restricted stock units issued during the nine months ended September 30, 2017 was $503,500. For the three and nine months ended September 30, 2017 and 2016, we recognized $80,125 and $121,555 and $248,804 and $748,573, respectively, of stock-based compensation expense for the vested units. As of September 30, 2017, compensation expense related to unvested shares not yet recognized in the condensed consolidated statement of operations was approximately $586,000 and will be recognized over a remaining weighted-average term of 2.2 years. Warrants During the year ended December 31, 2014, we issued warrants in connection with notes payable (which were repaid in 2013). The remaining warrants of 135,816 have an exercise price of $0.10 and expire December 6, 2018. In January 2015, we issued 250,000 warrants with an exercise price of $0.30 per share to a former executive in connection with the January 2015 debenture. The warrants expire on January 21, 2020. The warrants contain anti-dilution protection, including protection upon dilutive issuances. In connection with the convertible debentures issued in 2015, the exercise price of these warrants was reduced to $0.0896 per share and an additional 586,705 warrants were issued per the anti-dilution protection afforded in the warrant agreement during the year ended December 31, 2015. In connection with the convertible debentures in 2015, we issued warrants with an exercise price of $0.30 per share and expire in 2020 to investors and placement agents. Warrants to purchase 774,533 shares of common stock remain outstanding as of September 30, 2017. In connection with the 2016 Notes, we issued warrants to the Investors and placement agents with an exercise price of $0.40 per share and expire in 2021. Warrants to purchase 4,220,000 shares of common stock remain outstanding as of September 30, 2017. In connection with the public equity offering in March 2017, we issued Series A Warrants to purchase 25,666,669 shares of common stock at $0.15 per share and Series B Warrants to purchase 25,666,669 shares of common stock at $0.15 per share. The Series A Warrants expire in 2022 and the Series B Warrants expire in 2018. We also issued warrants to purchase 1,283,333 shares of common stock to our placement agent with an exercise price of $0.1875 per share and expire in 2022. For the nine months ended September 30, 2017, the following weighted average assumptions were utilized for the calculation of the fair value of the warrants issued during the period using Black-Scholes: 2017 Expected life (in years) 3.1 Expected volatility 203.3 % Average risk-free interest rate 1.49 % Dividend yield 0 % At September 30, 2017, there are 58,583,725 fully vested warrants outstanding. The weighted average exercise price of outstanding warrants at September 30, 2017 is $0.17 per share, the weighted average remaining contractual term is 2.6 years and the aggregate intrinsic value of the outstanding warrants is $837. Net Loss per Share Restricted stock units that are vested but the issuance and delivery of the shares are deferred until the employee or director resigns are included in the basic and diluted net loss per share calculations. The weighted average shares of common stock outstanding used in the basic and diluted net loss per share calculation for the three and nine months ended September 30, 2017 and 2016 was 152,250,793 and 143,192,157 and 97,222,394 and 77,645,019, respectively. The weighted average restricted stock units vested but issuance of the common stock is deferred until there is a change in control, a specified date in the agreement or the employee or director resigns used in the basic and diluted net loss per share calculation for the three and nine months ended September 30, 2017 and 2016 was 9,337,141 and 9,133,039 and 7,750,251 and 8,853,215, respectively. The total weighted average shares outstanding used in the basic and diluted net loss per share calculation for the three and nine months ended September 30, 2017 and 2016 was 161,587,934 and 152,325,196 and 104,972,645 and 86,498,234, respectively. The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted net loss per common share as of September 30, 2017 and 2016: As of September 30, 2017 2016 Gross number of shares excluded: Restricted stock units – unvested 3,437,500 5,012,499 Stock options 79,000 228,500 Convertible debentures and accrued interest - 7,651,830 Warrants 58,583,725 5,967,054 Total 62,100,225 18,859,883 The above table does not include the ANDA Consideration Shares related to the Novalere acquisition totaling 138,859 and 12,947,655 at September 30, 2017 and 2016, respectively, as they are considered contingently issuable (see Note 3).

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2017
Derivative Liability [Abstract]
DERIVATIVE LIABILITIES	The warrants issued in connection with the January 2015 Non-Convertible Debenture to a former executive are measured at fair value and classified as a liability because these warrants contain anti-dilution protection and therefore, cannot be considered indexed to our own stock which is a requirement for the scope exception as outlined under FASB ASC 815. The estimated fair value of the warrants was determined using the Probability Weighted Black-Scholes Model. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The anti-dilution protection for the warrants survives for the life of the warrants which ends in January 2020. The derivative liabilities are a Level 3 fair value measure in the fair value hierarchy and the assumptions for the Probability Weighted Black-Scholes Option-Pricing Model for the nine months ended September 30, 2017 are represented in the table below: September 30, 2017 Expected life (in years) 2.31 – 2.97 Expected volatility 173% – 187% Average risk-free interest rate 1.33% – 1.50% Dividend yield 0% We have determined the embedded conversion features of the 2016 Notes (see Note 5) to be derivative liabilities because the terms of the embedded conversion features contained anti-dilution protection and therefore, could not be considered indexed to our own stock which was a requirement for the scope exception as outlined under FASB ASC 815. The embedded conversion features were to be measured at fair value and classified as a liability with subsequent changes in fair value recorded in earnings at the end of each reporting period. We have determined the fair value of the derivative liabilities using a Path-Dependent Monte Carlo Simulation Model. The fair value of the derivative liabilities using such model was affected by changes in inputs to that model and was based on the individual characteristics of the embedded conversion features on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate, credit spread, probability of default by us and acquisition of us. During the nine months ended September 30, 2017, the 2016 Notes were either converted into shares of common stock or repaid in full. The conversion of the 2016 Notes during the nine months ended September 30, 2017 resulted in the fair value of the embedded conversion feature derivative liability on the dates of conversion of $203,630 to be reclassified to additional paid-in capital (see Note 7). Upon repayment of the remaining 2016 Notes in March 2017 (see Note 5), the fair value of the embedded conversion features on date of repayment of $238,101 was extinguished and included in loss on debt extinguishment in the accompanying condensed consolidated statement of operations. The derivative liabilities are a Level 3 fair value measurement in the fair value hierarchy and a summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for our embedded conversion feature derivative liabilities that are categorized within Level 3 of the fair value hierarchy during the nine months ended September 30, 2017 is as follows: September 30, 2017 Stock price $0.103 – $0.305 Strike price $0.25 Expected life (in years) 0.36 – 0.43 Expected volatility 130% – 168% Average risk-free interest rate 0.78% – 0.87% Dividend yield – At September 30, 2017, the estimated Level 3 fair value of the warrant derivative liabilities measured on a recurring basis is as follows: Fair value Level 1 Level 2 Level 3 Total Warrant derivative liabilities $ 74,151 $ - $ - $ 74,151 $ 74,151 The following table presents the activity for the Level 3 embedded conversion feature and warrant derivative liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2017: Fair Value Measurements Using Level 3 Inputs Warrant derivative liabilities: Beginning balance December 31, 2016 $ 164,070 Change in fair value (89,919 ) Ending balance September 30, 2017 $ 74,151 Embedded conversion feature derivative liabilities: Beginning balance December 31, 2016 $ 319,674 Reclassification of fair value of embedded conversion feature derivative liability to additional paid-in capital upon conversions of 2016 Notes (203,630 ) Extinguishment of embedded conversion feature upon repayment of 2016 Notes (238,101 ) Change in fair value 122,057 Ending balance September 30, 2017 $ -

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitment And Contingencies
COMMITMENT AND CONTINGENCIES	In May 2017, we entered into a commercial agreement with West-Ward Pharmaceuticals International Limited (“WWPIL”), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY). Pursuant to the commercial agreement, WWPIL will provide us with the rights to launch our branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved ANDA No. 207957 in the U.S. in November 2017. The initial term of the commercial agreement is for two years, and upon expiration of the initial term, the agreement will automatically renew for subsequent one-year terms unless either party notifies the other party in writing of its desire not to renew at least 90 days prior to the end of the then current term. The agreement requires us to meet certain minimum product batch purchase requirements in order for the agreement to continue to be in effect.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	In October and November 2017, we issued 235,996 shares of common stock to consultants for services rendered. The fair value of the common stock issued was approximately $21,000. On October 4, 2017, we entered into a securities exchange agreement with certain of the 2016 and 2017 Notes Payable holders. In connection with the securities exchange agreements, we issued a total of 8,592,431 shares of common stock in exchange for the settlement of principal and interest due under the 2016 and 2017 Notes Payable totaling $515,546. The fair value of the shares of common stock issued was based on the market price of our common stock on the date of the securities exchange agreements. Due to the settlement of the principal and interest balance of $515,546 into shares of common stock, the transaction was recorded as a debt extinguishment and the fair value of the shares of common stock issued in excess of the settled principal and interest balance totaling approximately $306,000 was recorded as a loss on debt extinguishment. On October 10, 2017, we entered into a service agreement with a third party pursuant to which we agreed to issue, over the term of the agreement through October 10, 2018, 2,000,000 shares of common stock in exchange for services to be rendered. The payment of shares of common stock is to be made in equal monthly installments beginning on November 1, 2017. On November 1, 2017, we issued 166,666 shares to the third party with a fair value of the shares issued of approximately $14,000. In October 2017, we entered into a promissory note agreement with two unrelated third-party investors in which the investors loaned us gross proceeds of $500,000. The promissory notes have an OID of $100,000 and bear interest at the rate of 0% per annum. The principal amount of $600,000 is to be repaid in nine equal monthly installments of $66,667 beginning in November 2017. In October 2017, we entered into a commercial lease agreement for 16,705 square feet of office and warehouse space in San Diego, CA that will commence on December 1, 2017 and continues until April 30, 2023. The initial monthly base rent is $20,881 with an approximate 3% increase in the base rent amount on an annual basis. We hold an option to extend the lease an additional 5 years at the end of the initial term. The Company and the landlord of our previous office space mutually agreed to terminate the existing office lease agreement effective November 1, 2017 with no penalty or future lease payments required by the Company. We have evaluated subsequent events through the filing date of this Form 10-Q and determined that no additional subsequent events have occurred that would require recognition in the condensed consolidated financial statements or disclosures in the notes thereto other than as disclosed in the accompanying notes to the condensed consolidated financial statements.

ORGANIZATION AND SUMMARY OF S16

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization	Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus”, “we”, “our”, “us” or the “Company”) is a Nevada formed, San Diego, California-based emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. We generate revenue from 22 commercial products in the United States, including six of these commercial products in multiple countries around the world through our commercial partners. Our commercial product portfolio includes (a) Beyond Human® Testosterone Booster, (b) Beyond Human® Growth Agent, (c) Zestra® to increase female arousal and desire, (d) EjectDelay® for premature ejaculation, (e) Sensum+® for reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) Androferti® to support overall male reproductive health and sperm quality, (i) RecalMax™ for cognitive brain health, (j) Beyond Human® Green Coffee Extract, (k) Beyond Human® Vision Formula, (l) Beyond Human® Blood Sugar, (m) Beyond Human® Colon Cleanse, (n) Beyond Human® Ketones, (o) Beyond Human® Krill Oil, (p) Beyond Human® Omega 3 Fish Oil, (q) UriVarx™ for bladder health, (r) ProstaGorx™ for prostate health, (s) AllerVarx ™ ™, Pipeline Products FlutiCare™ (fluticasone propionate nasal spray) Xyralid ™ . Urocis ™ XR AndroVit ™ In addition to the above listed product pipeline, we are continuously looking to add additional drugs, supplements and medical devices to our pipeline.
Basis Of Presentation And Principles Of Consolidation	The condensed consolidated balance sheet as of December 31, 2016, which has been derived from audited consolidated financial statements, and these unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc., Semprae Laboratories, Inc. (“Semprae”) and Novalere, Inc. (“Novalere”). All material intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016. Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The results for the period ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2017 or for any future period. Certain items have been reclassified to conform to the current year presentation.
Use of Estimates	The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include the allowance for doubtful accounts, sales returns and chargebacks, realizability of inventories, valuation of deferred tax assets, goodwill and intangible assets, valuation of contingent acquisition consideration, recoverability of long-lived assets and goodwill, fair value of derivative liabilities and the valuation of equity-based instruments and beneficial conversion features. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
Liquidity	Our operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of our common stock and revenue generated from our products domestically and internationally by our partners. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of September 30, 2017, we had an accumulated deficit of $34,144,243 and a working capital deficit of $1,239,906. In March 2017, we raised net cash proceeds of $3,307,773 from the sale of common stock and warrants in a registered public offering (see Note 7) and, in October 2017, September 2017, January 2017 and December 2016, we raised $1,300,000 in gross proceeds from the issuance of notes payable to four investors (see Notes 5 and 10). We have also issued equity instruments in certain circumstances to pay for services from vendors and consultants. As of September 30, 2017, we had $1,315,059 in cash. During the nine months ended September 30, 2017, we had net cash used in operating activities of $1,546,527. We expect that our existing capital resources, the proceeds received from the issuance of notes payable in October 2017 totaling $500,000 (see Note 10), revenue from sales of our products and upcoming sales milestone payments from the commercial partners signed for our products will be sufficient to allow us to continue our operations, commence the product development process and launch selected products through at least the next 12 months. In addition, our CEO, who is also a significant shareholder, has deferred the remaining payment of his salary earned through June 30, 2016 totaling $1,531,904 for at least the next 12 months. Our actual needs will depend on numerous factors, including timing of introducing our products to the marketplace, our ability to attract additional international distributors for our products and our ability to in-license in non-partnered territories and/or develop new product candidates. Although no assurances can be given, we currently intend to raise additional capital through the sale of debt or equity securities to provide additional working capital, pay for further expansion and development of our business, and to meet current obligations. Such capital may not be available to us when we need it or on terms acceptable to us, if at all.
Fair Value Measurement	Our financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, derivative liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair values of the warrant derivative liabilities and embedded conversion feature derivative liabilities are based upon the Black Scholes Option Pricing Model (“Black-Scholes”) and the Path-Dependent Monte Carlo Simulation Model calculations, respectively, and are a Level 3 measurement (see Note 8). The fair value of the contingent acquisition consideration is based upon the present value of expected future payments under the terms of the agreements and is a Level 3 measurement (see Note 3). Based on borrowing rates currently available to us, the carrying values of the notes payable approximate their respective fair values. We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: ● Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access at the measurement date. ● Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly. ● Level 3 measurements are unobservable inputs.
Concentration of Credit Risk and Major Customers	Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of sales of Zestra® to U.S. based retailers and Ex-U.S. partners. We also require a percentage of payment in advance for product orders with our larger partners. We perform ongoing credit evaluations of our customers and generally do not require collateral. Revenues consist primarily of product sales and licensing rights to market and commercialize our products. We have no customers that accounted for 10% or more of our total net revenue during the three and nine months ended September 30, 2017 and 2016 and three customers accounted for 76% and 62% of total net accounts receivable as of September 30, 2017 and December 31, 2016, respectively. Over 95% of our sales are currently within the United States and Canada. The balance of the sales are to various other countries, none of which is 10% or greater. We operate our business on the basis of a single reportable segment, which is the business of delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. Our chief operating decision-maker is the Chief Executive Officer, who evaluates us as a single operating segment.
Revenue Recognition and Deferred Revenue	We generate revenue from product sales and the licensing of the rights to market and commercialize our products. We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition Product Sales License Revenue Milestone Method
Sales Allowances	We accrue for product returns, volume rebates and promotional discounts in the same period the related sale is recognized. Our product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. We estimate our volume rebates and promotional discounts accrual based on its estimates of the level of inventory of our products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by our customers. In all cases, judgment is required in estimating these reserves. Actual claims for rebates and returns and promotional discounts could be materially different from the estimates. We provide a customer satisfaction warranty on all of our products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated. The estimated reserve for sales returns and allowances, which is included in accounts payable and accrued expense, was approximately $44,000 and $61,000 at September 30, 2017 and December 31, 2016, respectively.
Advertising Expense	Advertising costs, which primarily includes print and online media advertisements, are expensed as incurred and are included in sales and marketing expense in the accompanying condensed consolidated statements of operations. Advertising costs were approximately $1,350,000 and $1,424,000 and $3,961,000 and $1,604,000 for the three and nine months ended September 30, 2017 and 2016, respectively.
Debt Extinguishment	Any gain or loss associated with debt extinguishment is recorded in the period in which the debt is considered extinguished. Third party fees incurred in connection with a debt restructuring accounted for as an extinguishment are capitalized. Fees paid to third parties associated with a term debt restructuring accounted for as a modification are expensed as incurred. Third party and creditor fees incurred in connection with a modification to a line of credit or revolving debt arrangements are considered to be associated with the new arrangement and are capitalized.
Net Loss per Share	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested but deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the three and nine months ended September 30, 2017 and 2016, basic net loss per share is the same as diluted net loss per share as a result of our common stock equivalents being anti-dilutive. See Note 7 for more details.
Recent Accounting Pronouncements	In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting Compensation - Stock Compensation ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. As a result of the adoption of this ASU as of January 1, 2017, we have made an entity-wide accounting policy election to account for forfeitures when they occur. There is no cumulative-effect adjustment as a result of the adoption of this ASU as our estimated forfeiture rate prior to adoption of this ASU was 0%. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. We plan to adopt the standard on January 1, 2018. We currently believe that once we do adopt this standard, we will use the modified retrospective approach. Under the modified approach, an entity recognizes “the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application” (revenue in periods presented in the consolidated financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the consolidated financial statement line items and respective amounts directly affected by the standard’s application. While we are still currently assessing the impact of the new standard, our revenue is primarily generated from the sale of finished product to customers. Those sales predominantly contain a single delivery element and revenue is recognized at a single point in time when ownership, risks and rewards transfer. The timing of revenue recognition for these product sales are not materially impacted by the new standard. However, we are utilizing a comprehensive approach to assess the impact of the guidance on our current contract portfolio by reviewing our current accounting policies and practices to identify potential differences that would result from applying the new requirements to our revenue contracts, including evaluation of performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and accounting treatment of costs to obtain and fulfill contracts. We continue to make significant progress on the potential impact on our accounting policies and internal control processes including system readiness. In addition, we will update certain disclosures, as applicable, included in our filings pursuant to the Securities Exchange Act of 1934, as amended, to meet the requirements of the new guidance. In February 2016, the FASB issued ASU 2016-02, Leases

ASSETS AND LIABILITIES (Tables)

ASSETS AND LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2017
ASSETS
Schedule of Inventory	September 30, December 31, 2017 2016 Raw materials and supplies $ 194,895 $ 85,816 Work in process 62,786 48,530 Finished goods 382,374 465,510 Total $ 640,055 $ 599,856
Schedule of Intangible Assets	September 30, 2017 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 (116,408 ) $ 301,189 7 – 15 Customer Contracts 611,119 (234,262 ) 376,857 10 Sensum+® License (from CRI) 234,545 (101,600 ) 132,945 10 Vesele® Trademark 25,287 (9,418 ) 15,869 8 Beyond Human® Website and Trade Name 222,062 (62,360 ) 159,702 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,238,515 ) 3,442,485 10 Other Beyond Human® Intangible Assets 4,730 (3,205 ) 1,525 1 – 3 $ 6,196,340 $ (1,765,768) $ 4,430,572 December 31, 2016 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (91,201 ) $ 326,396 7 – 15 Customer Contracts 611,119 (188,428 ) 422,691 10 Sensum+® License (from CRI) 234,545 (84,009 ) 150,536 10 Vesele® Trademark 25,287 (7,047 ) 18,240 8 Beyond Human® Website and Trade Name 222,062 (32,821 ) 189,241 5 – 10 Novalere Manufacturing Contract 4,681,000 (887,440 ) 3,793,560 10 Other Beyond Human® Intangible Assets 4,730 (2,147 ) 2,583 1 – 3 Total $ 6,196,340 $ (1,293,093 ) $ 4,903,247
Schedule of future amortization expense for intangible assets	Remainder of 2017 $ 157,000 2018 630,000 2019 629,000 2020 629,000 2021 600,000 2022 592,000 Thereafter 1,194,000 $ 4,431,000
Prepaid expenses and other current assets	September 30, December 31, 2017 2016 Prepaid insurance $ 75,522 $ 69,976 Prepaid inventory 80,208 20,750 Merchant net settlement reserve receivable - 221,243 Prepaid consulting and other expense 64,825 21,094 Prepaid CRI royalties (see Note 2) 44,662 - Prepaid consulting and other service stock-based compensation expense (see Note 7) - 530,601 Total $ 265,217 $ 863,664
Accounts payable and accrued expenses	September 30, December 31, 2017 2016 Accounts payable $ 1,105,875 $ 647,083 Accrued credit card balances 43,614 31,654 Accrued royalties 129,022 73,675 Sales returns and allowances 44,051 60,853 Accrual for stock to be issued to consultants (see Note 7) - 360,000 Accrued other 33,495 36,785 Total $ 1,356,057 $ 1,210,050

NOTES PAYABLE AND DEBENTURES 18

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Payable [Abstract]
Schedule of Notes Payable	2017 2016 Notes payable: February 2016 Note Payable $ 133,997 $ 347,998 December 2016 and September 2017 Notes Payable 660,000 550,000 Total notes payable 793,997 897,998 Less: Debt discount (71,531 ) (216,871 ) Carrying value 722,466 681,127 Less: Current portion (722,466 ) (626,610 ) Notes payable, net of current portion $ - $ 54,517
Future minimum payments notes payable	Remainder of 2017 $ 574,012 2018 219,985 $ 793,997
Outstanding convertible debentures	2017 2016 Convertible debentures $ - $ 1,559,922 Less: Debt discount - (845,730 ) Carrying value - 714,192 Less: Current portion - (714,192 ) Convertible debentures, net of current portion $ - $ -

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Schedule of Accrued Compensation	September 30, 2017 December 31, 2016 Wages $ 1,431,686 $ 1,455,886 Vacation 323,163 261,325 Bonus 843,262 449,038 Payroll taxes on the above 134,980 133,344 Total 2,733,091 2,299,593 Classified as long-term (1,531,904 ) (1,531,904 ) Accrued compensation $ 1,201,187 $ 767,689

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2017
Stockholders Deficit Tables
Schedule Of Assumptions Used	2017 2016 Expected life (in years) 8.9 10.0 Expected volatility 215.4 % 227.8 % Average risk-free interest rate 2.27 % 1.71 % Dividend yield 0 % 0 % Grant date fair value $ 0.17 $ 0.17 2017 Expected life (in years) 3.1 Expected volatility 203.3 % Average risk-free interest rate 1.49 % Dividend yield 0 %
Schedule of Share-based Compensation, Stock Options	Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2016 237,500 $ 0.22 8.6 $ 14,293 Granted 37,000 0.17 - - Exercised (71,500 ) 0.07 - - Cancelled (124,000 ) 0.31 - - Forfeited - - - - Outstanding at September 30, 2017 79,000 $ 0.18 9.1 $ 468 Vested and Expected to Vest at September 30, 2017 79,000 $ 0.18 9.1 $ 468
Schedule of Share-based Compensation, Restricted Stock Units	Restricted Stock Units Outstanding at December 31, 2016 12,874,848 Granted 2,777,119 Exchanged (92,000 ) Cancelled (2,500,000 ) Outstanding at September 30, 2017 13,059,967 Vested at September 30, 2017 9,622,467
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of September 30, 2017 2016 Gross number of shares excluded: Restricted stock units – unvested 3,437,500 5,012,499 Stock options 79,000 228,500 Convertible debentures and accrued interest - 7,651,830 Warrants 58,583,725 5,967,054 Total 62,100,225 18,859,883

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Liability [Abstract]
Non-Convertible Debenture Assumptions	September 30, 2017 Expected life (in years) 2.31 – 2.97 Expected volatility 173% – 187% Average risk-free interest rate 1.33% – 1.50% Dividend yield 0%
Summary of quantitative information with respect to valuation methodology	September 30, 2017 Stock price $0.103 – $0.305 Strike price $0.25 Expected life (in years) 0.36 – 0.43 Expected volatility 130% – 168% Average risk-free interest rate 0.78% – 0.87% Dividend yield –
Fair value warrant derivative liabilities measured on a recurring basis	Fair value Level 1 Level 2 Level 3 Total Warrant derivative liabilities $ 74,151 $ - $ - $ 74,151 $ 74,151
Level 3 Warrant derivative liabilities measured at fair value	Warrant derivative liabilities: Beginning balance December 31, 2016 $ 164,070 Change in fair value (89,919 ) Ending balance September 30, 2017 $ 74,151 Embedded conversion feature derivative liabilities: Beginning balance December 31, 2016 $ 319,674 Reclassification of fair value of embedded conversion feature derivative liability to additional paid-in capital upon conversions of 2016 Notes (203,630 ) Extinguishment of embedded conversion feature upon repayment of 2016 Notes (238,101 ) Change in fair value 122,057 Ending balance September 30, 2017 $ -

ORGANIZATION AND SUMMARY OF S22

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Accumulated Deficit	$ 34,144,243		$ 34,144,243		$ 29,135,749
Working capital deficit	1,239,906		1,239,906		1,704,084
Cash and Cash Equivalents	1,315,059		1,315,059
Net cash used in operating activities			(1,546,527)	$ (739,472)
Estimated reserve for sales returns and allowances	44,000		44,000		$ 61,000
Advertising expense	$ 1,350,000	$ 3,961,000	$ 1,424,000	$ 1,604,000
Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk, Percentage			76.00%
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage					62.00%

LICENSE AGREEMENTS (Details Nar

LICENSE AGREEMENTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Densmore [Member]
Revenue from sales of products	$ 100,431		$ 100,431
Luminarie [Member]
Revenue from sales of products	0		0
J&H Co. LTD Agreement [Member]
Revenue from sales of products	0		60,000
Sothema Laboratories Agreement [Member]
Revenue from sales of products	0	$ 0	666	$ 12,229
Orimed Pharma Agreement [Member]
Revenue from sales of products	$ 11,230	$ 32,143	$ 40,233	$ 49,376

BUSINESS AND ASSET ACQUISITIO24

BUSINESS AND ASSET ACQUISITIONS (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Sep. 06, 2016
Semprae Laboratories [Member]
Business Acquisition [Line Items]
Fair Market Value of Contingent Consideration	$ 232,225	$ 405,577
Beyond Human [Member]
Business Acquisition [Line Items]
Fair Market Value of Contingent Consideration			$ 330,000

ASSETS AND LIABILITIES (Details

ASSETS AND LIABILITIES (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Assets Details
Raw materials and supplies	$ 194,895	$ 85,816
Work in process	62,786	48,530
Finished goods	382,374	465,510
Total	$ 640,055	$ 599,856

ASSETS AND LIABILITIES (Detai26

ASSETS AND LIABILITIES (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Intangible assets, Amount	$ 6,196,340	$ 6,196,340
Intangible assets, Accumulated Amortization	(1,765,768)	(1,293,093)
Intangible assets, Net Amount	4,430,572	4,903,247
Customer Contracts [Member]
Intangible assets, Amount	611,119	611,119
Intangible assets, Accumulated Amortization	(234,262)	(188,428)
Intangible assets, Net Amount	$ 376,857	$ 422,691
Intangible assets, Useful Lives (years)	10 years	10 years
Sensum License [Member]
Intangible assets, Amount	$ 234,545	$ 234,545
Intangible assets, Accumulated Amortization	(101,600)	(84,009)
Intangible assets, Net Amount	$ 132,945	$ 150,536
Intangible assets, Useful Lives (years)	10 years	10 years
Patents and Trademarks [Member]
Intangible assets, Amount	$ 417,597	$ 417,597
Intangible assets, Accumulated Amortization	(116,408)	(91,201)
Intangible assets, Net Amount	$ 301,189	$ 326,396
Patents and Trademarks [Member] | Minimum [Member]
Intangible assets, Useful Lives (years)	7 years	7 years
Patents and Trademarks [Member] | Maximum [Member]
Intangible assets, Useful Lives (years)	15 years	15 years
Other Beyond Human Intangible Assets [Member]
Intangible assets, Amount	$ 4,730	$ 4,730
Intangible assets, Accumulated Amortization	(3,205)	(2,147)
Intangible assets, Net Amount	$ 1,525	$ 2,583
Other Beyond Human Intangible Assets [Member] | Minimum [Member]
Intangible assets, Useful Lives (years)	1 year	1 year
Other Beyond Human Intangible Assets [Member] | Maximum [Member]
Intangible assets, Useful Lives (years)	3 years	3 years
Beyond Human [Member]
Intangible assets, Amount	$ 222,062	$ 222,062
Intangible assets, Accumulated Amortization	(62,360)	(32,821)
Intangible assets, Net Amount	$ 159,702	$ 189,241
Beyond Human [Member] | Minimum [Member]
Intangible assets, Useful Lives (years)	5 years	5 years
Beyond Human [Member] | Maximum [Member]
Intangible assets, Useful Lives (years)	10 years	10 years
Vesele [Member]
Intangible assets, Amount	$ 25,287	$ 25,287
Intangible assets, Accumulated Amortization	(9,418)	(7,047)
Intangible assets, Net Amount	$ 15,869	$ 18,240
Intangible assets, Useful Lives (years)	8 years	8 years
Novalere Mfg. Contract [Member]
Intangible assets, Amount	$ 4,681,000	$ 4,681,000
Intangible assets, Accumulated Amortization	(1,238,515)	(887,440)
Intangible assets, Net Amount	$ 3,442,485	$ 3,793,560
Intangible assets, Useful Lives (years)	10 years	10 years

ASSETS AND LIABILITIES (Detai27

ASSETS AND LIABILITIES (Details 2) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Assets Details
Remainder of 2017	$ 157,000
2,018	630,000
2,019	629,000
2,020	629,000
2,021	600,000
2,022	592,000
Thereafter	1,194,000
Total	$ 4,430,572	$ 4,903,247

ASSETS AND LIABILITIES (Detai28

ASSETS AND LIABILITIES (Details 3) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Assets And Liabilities Details 3
Prepaid insurance	$ 75,522	$ 69,976
Prepaid inventory	80,208	20,750
Merchant net settlement reserve receivable	0	221,243
Prepaid consulting and other expenses	64,825	21,094
Prepaid CRI royalties (see Note 2)	44,662	0
Prepaid consulting and other service stock-based compensation expense (see Note 7)	0	530,601
Total	$ 265,217	$ 863,664

ASSETS AND LIABILITIES (Detai29

ASSETS AND LIABILITIES (Details 4) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Assets And Liabilities Details 4
Accounts payable	$ 1,105,875	$ 647,083
Accrued credit card balances	43,614	31,654
Accrued royalties	129,022	73,675
Sales returns and allowances	44,051	60,853
Accrual for stock to be issued to consultants (see Note 7)	0	360,000
Accrued other	33,495	36,785
Total	$ 1,356,057	$ 1,210,050

ASSETS AND LIABILITIES (Detai30

ASSETS AND LIABILITIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Assets Details Textual
Amortization expense	$ 157,477	$ 178,082	$ 472,675	$ 513,767

NOTES PAYABLE AND DEBENTURES 31

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total notes payable and convertible debentures	$ 793,997	$ 897,998
Less: Debt discount	(71,531)	(216,871)
Carrying value	722,466	681,127
Less: Current portion	(722,466)	(626,610)
Notes payable and convertible debentures, net of current portion	0	54,517
February 2016 Note Payable [Member]
Total notes payable and convertible debentures	133,997	347,998
December 2016 and January 2017 Notes Payable [Member]
Total notes payable and convertible debentures	$ 660,000	$ 550,000

NOTES PAYABLE AND DEBENTURES 32

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES (Details 1)	Sep. 30, 2017USD ($)
Notes Payable [Abstract]
Remainder of 2017	$ 574,012
2,018	219,985
Total	$ 793,997

NOTES PAYABLE AND DEBENTURES 33

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES (Details 2) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Notes Payable [Abstract]
Convertible debentures	$ 0	$ 1,559,922
Less: Debt discount	0	(845,730)
Carrying value	0	714,192
Less: Current portion	0	(714,192)
Convertible debentures, net of current portion	$ 0	$ 0

NOTES PAYABLE AND DEBENTURES 34

NOTES PAYABLE AND DEBENTURES - NON-RELATED PARTIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Notes Payable [Abstract]
Interest expense	$ 104,276	$ 3,719,200	$ 771,885	$ 5,970,450
Amortization of Debt Discount			$ 687,598	$ 2,997,061

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Related Party Transactions Details
Wages	$ 1,431,686	$ 1,455,886
Vacation	323,163	261,325
Bonuses	843,262	449,038
Payroll Taxes on the above	134,980	133,344
Total	2,733,091	2,299,593
Classified as long-term	(1,531,904)	(1,531,904)
Accrued compensation	$ 1,201,187	$ 767,689

STOCKHOLDERS_ EQUITY (Details)

STOCKHOLDERS’ EQUITY (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Dividend yield	0.00%
Warrants [Member]
Expected life (in years)	3 years 1 month 6 days
Expected volatility	203.30%
Average risk free interest rate	1.49%
Dividend yield	0.00%
Stock Options [Member]
Expected life (in years)	8 years 10 months 24 days	10 years
Expected volatility	215.40%	227.80%
Average risk free interest rate	2.27%	1.71%
Dividend yield	0.00%	0.00%
Grant date fair value	$ 0.17	$ 0.17

STOCKHOLDERS_ EQUITY (Details 1

STOCKHOLDERS’ EQUITY (Details 1) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares
Stock Options, Outstanding Beginning Balance | shares	237,500
Options, Granted | shares	37,000
Options, Exercised | shares	(71,500)
Options, Cancelled | shares	(124,000)
Options, Forfeited | shares	0
Stock Options, Outstanding Ending Balance | shares	79,000
Options, Vested | shares	79,000
Weighted average exercise price, Outstanding Beginning Balance | $ / shares	$ 0.22
Weighted average exercise price, Granted | $ / shares	0.17
Weighted average exercise price, Exercised | $ / shares	0.07
Weighted average exercise price, Cancelled | $ / shares	0.31
Weighted average exercise price, Forfeited | $ / shares	0
Weighted average exercise price, Outstanding Ending Balance | $ / shares	0.18
Weighted average exercise price, Vested | $ / shares	$ 0.18
Weighted remaining contractual life (years), Outstanding	8 years 7 months 6 days
Weighted remaining contractual life (years) Outstanding	9 years 1 month 6 days
Weighted remaining contractual life (years), Vested	9 years 1 month 6 days
Aggregate intrinsic value, Outstanding, beginning | $	$ 14,293
Aggregate intrinsic value, Outstanding, end | $	468
Aggregate intrinsic value, Vested | $	$ 468

STOCKHOLDERS_ EQUITY (Details 2

STOCKHOLDERS’ EQUITY (Details 2) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2017shares
Outstanding at December 31, 2016	12,874,848
Granted	2,777,119
Exchanged	(92,000)
Cancelled	(2,500,000)
Outstanding at September 30, 2017	13,059,967
Vested at September 30, 2017	9,622,467

STOCKHOLDERS_ EQUITY (Details 3

STOCKHOLDERS’ EQUITY (Details 3) - shares	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	62,100,225	18,859,883
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,583,725	5,967,054
Convertible debentures and accrued interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	7,651,830
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,000	228,500
Restricted stock units - unvested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,437,500	5,012,499

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Vested Warrants	58,583,725		58,583,725
Total weighted average shares outstanding used in the basic and diluted net loss per share calculation	161,587,934	104,972,645	152,325,196	86,498,234
2016 Equity Plan [Member]
Available for future grant	21,140,750		21,140,750
2013 Equity Plan [Member]
Available for future grant	106,000		106,000
2014 Equity Plan [Member]
Available for future grant	58,367		58,367
Stock Options [Member]
Stock-Based Compensation Expense	$ 904	$ 6,310	$ 8,638	$ 18,138
Weighted average shares of common stock outstanding used in the basic and diluted net loss per share calculation	152,250,793	97,222,394	143,192,157	77,645,019
Restricted Stock Units [Member]
Stock-Based Compensation Expense		$ 248,804		$ 748,573
Weighted average restricted stock units vested but deferred until the employee or director resigns outstanding used in the basic and diluted net loss per share		7,750,251		8,853,215
Restricted Stock Units [Member]
Stock-Based Compensation Expense	$ 80,125		$ 121,555
Weighted average restricted stock units vested but deferred until the employee or director resigns outstanding used in the basic and diluted net loss per share	9,337,141		9,133,039

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details)	9 Months Ended
	Sep. 30, 2017
Dividend yield	0.00%
Derivative Liabilities | Minimum [Member]
Expected life (in years)	2 years 3 months 22 days
Expected volatility	173.00%
Average risk free interest rate	1.33%
Derivative Liabilities | Maximum [Member]
Expected life (in years)	2 years 11 months 19 days
Expected volatility	187.00%
Average risk free interest rate	1.50%

DERIVATIVE LIABILITIES (Detai42

DERIVATIVE LIABILITIES (Details 1)	9 Months Ended
	Sep. 30, 2017$ / shares
Strike price	$ 0.25
Dividend yield	0.00%
Minimum [Member]
Stock price	$ 0.103
Expected life (in years)	4 months 10 days
Expected volatility	130.00%
Average risk free interest rate	0.78%
Maximum [Member]
Stock price	$ 0.305
Expected life (in years)	5 months 5 days
Expected volatility	168.00%
Average risk free interest rate	0.87%

DERIVATIVE LIABILITIES (Detai43

DERIVATIVE LIABILITIES (Details 2)	Sep. 30, 2017USD ($)
Warrant derivative liabilities	$ 74,151
Fair Value
Warrant derivative liabilities	74,151
Fair Value, Inputs, Level 1 [Member]
Warrant derivative liabilities	0
Fair Value, Inputs, Level 2 [Member]
Warrant derivative liabilities	0
Fair Value, Inputs, Level 3 [Member]
Warrant derivative liabilities	$ 74,151

DERIVATIVE LIABILITIES (Detai44

DERIVATIVE LIABILITIES (Details 3)	Sep. 30, 2017USD ($)
Warrant derivative liabilities
Beginning balance	$ 164,070
Change in Fair Value	(89,919)
Ending Balance	74,151
Embedded conversion feature derivative liabilities
Beginning Balance	319,674
Reclassification of fair value of embedded conversion feature derivative liability to additional paid-in capital upon conversions of 2016 Notes	(203,630)
Extinguishment of embedded conversion feature upon repayment of 2016 Notes	(238,101)
Change in Fair Value	122,057
Ending Balance	$ 0